-
Je něco špatně v tomto záznamu ?
Paediatric familial hypercholesterolaemia screening in Europe: public policy background and recommendations
SS. Gidding, A. Wiegman, U. Groselj, T. Freiberger, N. Peretti, KI. Dharmayat, M. Daccord, N. Bedlington, J. Sikonja, KK. Ray, RD. Santos, M. Halle, L. Tokgözoğlu, I. Gutiérrez-Ibarluzea, FJ. Pinto, M. Geanta
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
36059237
DOI
10.1093/eurjpc/zwac200
Knihovny.cz E-zdroje
- MeSH
- dítě MeSH
- genetické testování MeSH
- hyperlipoproteinemie typ II * diagnóza epidemiologie genetika MeSH
- LDL-cholesterol MeSH
- lidé MeSH
- nemoci srdce * MeSH
- plošný screening MeSH
- rizikové faktory MeSH
- veřejná politika MeSH
- Check Tag
- dítě MeSH
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Geografické názvy
- Evropa MeSH
Familial hypercholesterolaemia (FH) is under-recognized and under-treated in Europe leading to significantly higher risk for premature heart disease in those affected. As treatment beginning early in life is highly effective in preventing heart disease and cost-effective in these patients, screening for FH is crucial. It has therefore now been recognized by the European Commission Public Health Best Practice Portal as an effective strategy. Model programmes exist in Europe to identify young individuals with FH, which are based on cascade screening of first-degree relatives of affected individuals, universal screening for high cholesterol, opportunistic screening of high-risk individuals, or a combination of the above approaches. Recommendations presented herein to improve identification of FH emphasize that every country should have an FH screening programme. These programmes should be adapted from existing strategies to best fit the individual country's healthcare system, governments should provide financial support for these programmes and related care, and further research to optimize care and implementations should be conducted.
Cardiovascular Department CCUL CAML Lisbon School of Medicine University of Lisbon Portugal
Centre for Cardiovascular Surgery and Transplantation Pekařská 53 656 91 Brno Czech Republic
Department of Cardiology Hacettepe University Ankara Turkey
DZHK partner site Munich Munich Heart Alliance Munich Germany
Heart Institute University of Sao Paulo Medical School Hospital Sao Paulo Brazil
International Atherosclerosis Society Milan Italy
Medical Faculty Masaryk University Kamenice 5 625 00 Brno Czech Republic
The European FH Patient Network Star House Star Hill Rochester Kent ME1 1UX UK
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22032119
- 003
- CZ-PrNML
- 005
- 20230131151745.0
- 007
- ta
- 008
- 230120s2022 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1093/eurjpc/zwac200 $2 doi
- 035 __
- $a (PubMed)36059237
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Gidding, Samuel S $u The European FH Patient Network (FH Europe), Star House, Star Hill, Rochester, Kent ME1 1UX, UK $1 https://orcid.org/0000000285577225
- 245 10
- $a Paediatric familial hypercholesterolaemia screening in Europe: public policy background and recommendations / $c SS. Gidding, A. Wiegman, U. Groselj, T. Freiberger, N. Peretti, KI. Dharmayat, M. Daccord, N. Bedlington, J. Sikonja, KK. Ray, RD. Santos, M. Halle, L. Tokgözoğlu, I. Gutiérrez-Ibarluzea, FJ. Pinto, M. Geanta
- 520 9_
- $a Familial hypercholesterolaemia (FH) is under-recognized and under-treated in Europe leading to significantly higher risk for premature heart disease in those affected. As treatment beginning early in life is highly effective in preventing heart disease and cost-effective in these patients, screening for FH is crucial. It has therefore now been recognized by the European Commission Public Health Best Practice Portal as an effective strategy. Model programmes exist in Europe to identify young individuals with FH, which are based on cascade screening of first-degree relatives of affected individuals, universal screening for high cholesterol, opportunistic screening of high-risk individuals, or a combination of the above approaches. Recommendations presented herein to improve identification of FH emphasize that every country should have an FH screening programme. These programmes should be adapted from existing strategies to best fit the individual country's healthcare system, governments should provide financial support for these programmes and related care, and further research to optimize care and implementations should be conducted.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a dítě $7 D002648
- 650 _2
- $a LDL-cholesterol $7 D008078
- 650 _2
- $a rizikové faktory $7 D012307
- 650 12
- $a hyperlipoproteinemie typ II $x diagnóza $x epidemiologie $x genetika $7 D006938
- 650 _2
- $a veřejná politika $7 D011640
- 650 12
- $a nemoci srdce $7 D006331
- 650 _2
- $a plošný screening $7 D008403
- 650 _2
- $a genetické testování $7 D005820
- 651 _2
- $a Evropa $x epidemiologie $7 D005060
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Wiegman, Albert $u Department of Paediatrics, Amsterdam University Medical Centers, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands $1 https://orcid.org/0000000162235671
- 700 1_
- $a Groselj, Urh $u Department of Endocrinology, Diabetes, and Metabolic Diseases, University Children's Hospital, University Medical Centre Ljubljana, Bohoričeva ulica 20, Ljubljana, Slovenia
- 700 1_
- $a Freiberger, Tomas $u Centre for Cardiovascular Surgery and Transplantation, Pekařská 53, 656 91 Brno, Czech Republic $u Medical Faculty, Masaryk University, Kamenice 5, 625 00 Brno, Czech Republic
- 700 1_
- $a Peretti, Noel $u Department of Pediatric Gastroenterology-Hepatology and Nutrition, Hospices Civil de Lyon HCL, Hôpital Femme Mere Enfant HFME, Bron, France $u Univ-Lyon, CarMeN Laboratory, INSERM U1060, INRAE U1397, Université Claude Bernard Lyon-1, Oullins, Lyon, France
- 700 1_
- $a Dharmayat, Kanika I $u Imperial Centre for Cardiovascular Disease Prevention, Department of Primary Care and Public Health, Imperial College London, St Dunstan's Road, London W6 8RP, UK
- 700 1_
- $a Daccord, Magdalena $u The European FH Patient Network (FH Europe), Star House, Star Hill, Rochester, Kent ME1 1UX, UK
- 700 1_
- $a Bedlington, Nicola $u The European FH Patient Network (FH Europe), Star House, Star Hill, Rochester, Kent ME1 1UX, UK
- 700 1_
- $a Sikonja, Jaka $u Department of Endocrinology, Diabetes, and Metabolic Diseases, University Children's Hospital, University Medical Centre Ljubljana, Bohoričeva ulica 20, Ljubljana, Slovenia $1 https://orcid.org/0000000178438107
- 700 1_
- $a Ray, Kausik K $u Imperial Centre for Cardiovascular Disease Prevention, Department of Primary Care and Public Health, Imperial College London, St Dunstan's Road, London W6 8RP, UK
- 700 1_
- $a Santos, Raul D $u Heart Institute (InCor), University of Sao Paulo Medical School Hospital, Sao Paulo, Brazil $u Preventive Medicine Centre and Cardiology Program, Hospital Israelita Albert Einstein, Sao Paulo, Brazil $u International Atherosclerosis Society (IAS), Milan, Italy
- 700 1_
- $a Halle, Martin $u Department of Prevention and Sports Medicine, Faculty of Medicine, University Hospital 'Klinikum rechts der Isar', Technical University Munich, Munich, Germany $u DZHK (Deutsches Zentrum für Herz-Kreislauf-Forschung), partner site Munich, Munich Heart Alliance, Munich, Germany $1 https://orcid.org/000000033065530X
- 700 1_
- $a Tokgözoğlu, Lale $u Department of Cardiology, Hacettepe University, Ankara, Turkey
- 700 1_
- $a Gutiérrez-Ibarluzea, Iñaki $u Head of Knowledge Management and Health Technology Assessment, Basque Foundation for Health Innovation and Research (BIOEF), Ronda de Azkue, 1, 48902 Barakaldo (Bizkaia), Basque Country, Spain
- 700 1_
- $a Pinto, Fausto J $u World Heart Federation, Geneva, Switzerland $u Cardiovascular Department, CCUL, CAML, Lisbon School of Medicine, University of Lisbon, Portugal
- 700 1_
- $a Geanta, Marius $u The European FH Patient Network (FH Europe), Star House, Star Hill, Rochester, Kent ME1 1UX, UK
- 773 0_
- $w MED00188754 $t European journal of preventive cardiology $x 2047-4881 $g Roč. 29, č. 18 (2022), s. 2301-2311
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36059237 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230120 $b ABA008
- 991 __
- $a 20230131151741 $b ABA008
- 999 __
- $a ok $b bmc $g 1891101 $s 1183454
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2022 $b 29 $c 18 $d 2301-2311 $e 2022Dec21 $i 2047-4881 $m European journal of preventive cardiology $n Eur J Prev Cardiol $x MED00188754
- LZP __
- $a Pubmed-20230120
